Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy for 'Longevity Protein' klotho begins human testing

NCT ID NCT07216781

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 27 times

Summary

This early-phase study tests a gene therapy that delivers instructions for making Klotho protein, which is linked to brain and kidney health. Twenty-four healthy adults will receive a single injection to see if it safely raises Klotho levels and improves thinking or other body functions. The study focuses on safety and measuring changes in blood and urine markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Apeiron Center

    RECRUITING

    Austin, Texas, 78701, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • GARM Clinic

    NOT_YET_RECRUITING

    Roatán, Bay Islands, Honduras

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.